Semaglutide is the product of a long research lineage aimed at one problem: native GLP-1 breaks down within minutes, which limits how it can be studied.
Extending a short-lived peptide
Native glucagon-like peptide-1 is rapidly degraded by the enzyme DPP-4. Successive research generations of GLP-1 receptor agonists introduced modifications to resist that degradation and extend activity. Semaglutide represents a long-acting design in that lineage, engineered for a much longer research half-life than the native peptide.
Its place in the class
As a single-receptor GLP-1 agonist, semaglutide is a frequent baseline in comparative studies against dual and triple agonists — see semaglutide vs tirzepatide and the broader GLP-1 class overview.
Product page: Semaglutide research vials.
Research Use Only. Supplied strictly for laboratory research and development — not for human or veterinary use, consumption, or any therapeutic or diagnostic purpose. This article is research education, not usage guidance.